In vivo CAR-T
Bladder cancer, Merkel cell carcinoma, cutaneous squamous cell carcinoma, head and neck cancer
Key Facts
About Kernal Biologics
Kernal Biologics is developing a next-generation mRNA platform designed to overcome key limitations of current cell therapies by programming cells directly inside the body (in vivo). Its core innovation lies in two pillars: precise tissue/cell targeting using engineered LNPs to avoid liver sequestration, and AI-programmed selective mRNA translation to minimize off-target effects. The company is advancing a pipeline of in vivo CAR-T therapies for solid tumors and autoimmune disorders, backed by significant non-dilutive funding including a recent award from ARPA-H.
View full company profileAbout Kernal Biologics
Kernal Biologics is developing a next-generation mRNA platform designed to overcome key limitations of current cell therapies by programming cells directly inside the body (in vivo). Its core innovation lies in two pillars: precise tissue/cell targeting using engineered LNPs to avoid liver sequestration, and AI-programmed selective mRNA translation to minimize off-target effects. The company is advancing a pipeline of in vivo CAR-T therapies for solid tumors and autoimmune disorders, backed by significant non-dilutive funding including a recent award from ARPA-H.
View full company profileAbout Kernal Biologics
Kernal Biologics is developing a next-generation mRNA platform designed to overcome key limitations of current cell therapies by programming cells directly inside the body (in vivo). Its core innovation lies in two pillars: precise tissue/cell targeting using engineered LNPs to avoid liver sequestration, and AI-programmed selective mRNA translation to minimize off-target effects. The company is advancing a pipeline of in vivo CAR-T therapies for solid tumors and autoimmune disorders, backed by significant non-dilutive funding including a recent award from ARPA-H.
View full company profile